This years National OPAT Conference intends to build and grow on the successes of previous events and will once again bring together world renowned speakers and experts to discuss and learn about upcoming challenges in the OPAT setting
Cardiome’s mission is to offer patients and healthcare providers innovative therapeutic options that effectively, safely and conveniently manage acute medical conditions to improve health and quality of life
Cardiome has two marketed, in-hospital, cardiology products: BRINAVESS® (vernakalant HCl, IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT® (tirofiban HCl), a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome (ACS). Cardiome also commercializes ESMOCARD® and ESMOCARD LYO® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, including supraventricular tachycardia (SVT), on behalf of its partner AOP Orphan Pharma in select European markets, and co-promotes EXEMBOL® (argatroban monohydrate), an anticoagulant indicated for use in patients with heparin induced thrombocytopenia (HIT) type II, with Mitsubishi Tanabe Pharma Europe in the UK.
Cardiome has also licensed: XYDALBA™ (dalbavancin hydrochloride), a second generation, semi-synthetic lipoglycopeptide approved in the EU for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults for select European and Middle Eastern nations and Canada from Allergan; and TREVYENT®, a development stage drug device combination that is under development for Pulmonary Arterial Hypertension (PAH) for Europe, the Middle East and for Canadian markets from SteadyMed Therapeutics.